Macrogen Launches Special Promotion on Exome Sequencing
SEOUL, South Korea--The precision medicine biotech company Macrogen (CEO Chong Hyon-yong, www.macrogen.com) (KOSDAQ:038290), announced on August 10th that it is launching a special promotion on exome sequencing.
During this special promotion period, Macrogen will offer exome sequencing service with 100x coverage using SureSelect Human All Exome V4 (51M) or V5 (50M) capture kit at special price of $399 per sample.
Researchers around the world can take advantage of this Whole Exome Sequencing (WES) service on very special price terms. The WES service is characterized by efficient large data generation and fast Turnaround Time (TAT) that are d on the industry’s best next-generation sequencing service of Macrogen as well as its professional service know-hows.
To date, Macrogen has successfully provided the WES service for more than 35,000 human samples to customers around the world. In particular, Macrogen has recently achieved the capability of offering a world-class Exome Sequencing service, enabling it to sequence more than 10,000 human exomes per month, and over a maximum of 120,000 per year through the introduction of new platforms and upgrade of existing platforms.
By targeting and sequencing only the protein coding regions, which accounts for less than 2% of the entire genome, Exome Sequencing provides a cost efficient alternative to Whole Genome Sequencing (WGS). The researchers can efficiently conduct comparative sequencing research on large population samples by increasing the number of sequencing samples.
Macrogen CEO Chong Hyon-yong said, "This Exome Project Special Promotion has been planned to further strengthen Macrogen’s customer-centered service philosophy, which we have adhered to for the past 20 years or so to provide the best customer service through high-quality data, fast delivery, and competitive prices." He also added that "Macrogen is also planning various other promotions to support the research activities of global researchers in the near future."